Descovy (TAF/emtricitabine) is a fixed-dose tablet combining 200mg of emtricitabine and either 25mg or 10mg of tenofovir alafenamide (TAF). It is manufactured by Gilead Sciences.

Emtricitabine is a nucleoside reverse transcriptase inhibitor (NRTI) and tenofovir alafenamide is a nucleotide reverse transcriptase inhibitor (NtRTI). These drugs reduce the amount of HIV in the body.

The standard dose of Descovy is one pale blue tablet once a day, with or without food, in combination with at least one other anti-HIV drug. It is licensed for use in adults over 18 years of age. Descovy was approved for use in combination with another antiretroviral agent in April 2016 in the United States and European Union. The fixed-dose tablet containing 10mg of TAF is recommended for use when Descovy is used in combination with the protease inhibitors atazanavir, darunavir or lopinavir, boosted by either ritonavir or cobicistat.

For more information on Descovy’s component drugs, including drug interactions, side-effects and resistance, see emtricitabine (FTC, Emtriva) and tenofovir (Viread).

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.